Project Grant R01CA303799
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $767K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to St. Jude Children's Research Hospital Inc. provides $718,113 to fund research on "Targetable Epigenetic Modifiers that Promote Neuroblastoma Malignancy and Plasticity". The project aims to investigate how epigenetic factors, including histone deacetylases (HDAC) and histone lysine demethylase 4 family (KDM4), connect the MYC oncogenes to neuroblastoma-specific...
- The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.395 - Cancer Treatment Research to St. Jude Children's Research Hospital Inc. for $768,713 on August 1, 2025. The funding supports research to dissect how the EP300 and CBP histone acetyltransferase proteins control cell state-specific phenotypes and chemosensitivity in high-risk neuroblastoma. The objectives are to capitalize on transcriptional control to identify mechanism-based, targeted cancer therapies that can...
- This $531,550 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting research to discover novel druggable oncogenes that block neuroblastoma (NBL) cell differentiation and evaluate inhibitors of those oncogenes as potential differentiation therapy agents. The project aims to systematically screen the human druggable genome using a high-content siRNA screening approach to identify key oncogenes that prevent NBL cell...
- This federal Project Grant award for $1,679,104 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by St. Jude Children's Research Hospital Inc. to investigate pre-mRNA splicing as a potential therapeutic vulnerability for pediatric liver cancer. The award, with a performance period from September 30, 2025 to September 29, 2028, will fund sophisticated scientific research, including the development of novel...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $290,017.00 to St. Jude Children's Research Hospital Inc. to investigate the cell state hierarchy and transcriptional/epigenetic determinants of therapy-resistant progenitor-like cells in fusion-negative rhabdomyosarcoma (FN-RMS), a type of pediatric soft tissue sarcoma. The award will support computational and experimental research approaches, including single-cell RNA sequencing,...
- This Project Grant award of $562,869, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to define the role of chromosome 17q gain in the malignancy of neuroblastoma, the most common pediatric extracranial solid tumor. The principal investigators at Children's Hospital Los Angeles will use a human stem cell model of neuroblastoma to: 1) compare the tumorigenic potential of 17q gain and MYCN in immature cells...
- This Project Grant award for $1,340,665.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to St. Jude Children's Research Hospital Inc. The award supports research focused on the FGFR pathway as a lead therapeutic vulnerability in pediatric ependymoma, a type of brain cancer in children. The project will be conducted over 3 years, from September 1, 2023 to August 31, 2026, and aims to advance the development of effective...
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on developing novel therapeutic approaches to treat neuroblastoma, the most common extracranial solid pediatric cancer and a leading cause of cancer-related deaths in children. The $690,013 award to Pennsylvania State University's Milton S. Hershey Medical Center aims to target the role of extracellular vesicles (EVs) in neuroblastoma progression and metastasis. Specifically, the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to develop high-quality chemical probes to functionally annotate the epigenetic effector "reader" domains within the Bromodomain PHD Finger Transcription Factor (BPTF) in neuroblastoma, an aggressive pediatric cancer. The $738,024 award, effective from January 1, 2025 to December 31, 2029, aims to optimize BPTF bromodomain and plant homeodomain (PHD)...